Plain-English translation of NCT06910657 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a Phase I trial testing IDOV-Immune, a new cancer treatment made from a genetically engineered virus designed to infect and kill tumor cells while strengthening your immune system's ability to fight cancer. The medication has been modified to specifically target cancer cells while minimizing harm to healthy tissue. This is the first time the treatment is being tested in humans.
Many advanced cancers stop responding to standard treatments like chemotherapy and immunotherapy, leaving patients with few options. This medication takes a different approach by using a modified virus to directly attack tumors and wake up the immune system, potentially offering hope for patients who have exhausted other therapies.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication on Day 1 of each 28-day treatment cycle. Throughout the study, you will have frequent check-ins including physical exams, blood tests, and imaging scans to monitor how your body responds and whether the cancer is shrinking. The study is designed to carefully increase the dose over time in small groups of patients to find the safest and most effective dose, with the possibility that you may participate for several months depending on how well the treatment works and how you tolerate it.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Australia